Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cardiovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Cerebrovascular mortality + morbidity · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cerebrovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Coronary heart disease mortality + morbidity · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower coronary heart disease mortality and morbidity Mean duration of 2.9… compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults 60 years or older with primary hypertension
Antihypertensive drug may leads to higher withdrawals due to adverse effects Mean duration of 4.6 years compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events: hypotension · type 1 or type 2 diabetics
Blood pressure intervention/intensive blood pressure intervention may leads to higher adverse events—hypotension compared with placebo/standard blood pressure intervention (low certainty).
1 finding from 1 review
All‐cause mortality · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes cardiovascular events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes hospitalisation for heart failure compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes withdrawal due to adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Relapse · people with severe mental disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · people with severe mental disorders
Intensive Case Management may leads to lower global state: 1. Leaving the study early ‐ by long term compared with non‐Intensive Case Management (low certainty).
1 finding from 1 review
Social functioning 2. Employment status ‐ by medium term ‐ spent > 1 day employed · people with severe mental disorders
It is very uncertain whether intensive Case Management changes social functioning 2. Employment status ‐ by medium term ‐ spent > 1… compared with non‐Intensive Case Management (very low certainty).
1 finding from 1 review
Mental state: No clinically important improvement · people with severe mental disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use: 1. Average number of days in hospital per month ‐ by about 24 months · people with severe mental disorders
1 finding from 1 review
Service use: 3b. Average number of admissions (skewed data ‐ sample size ≧ 200) ‐ by long term · people with severe mental disorders
1 finding from 1 review
Adverse event: 1b. Death ‐ suicide ‐ by long term · people with severe mental disorders
Intensive Case Management showed no clear difference in adverse event: 1b. Death ‐ suicide ‐ by long term compared with non‐Intensive Case Management (low certainty).
1 finding from 1 review
Beta‐blocker (any dose) Mean duration of 4 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Calcium channel blocker (any dose) Mean duration of 3 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Beta‐blocker/thiazide combination (any dose) Mean duration of 10 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review